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EKSTRAK ETANOL ORTHOSIPHON STAMINEUS BENTH. 
MEMPAMERKAN KESAN ANTIOBESITI DENGAN MENGHALANG 
ANGIOGENESIS DAN LIPASE PANKREAS 
ABSTRAK 
 
 
Dalam kajian ini, kesan antiobesiti Orthosiphon stamineus (OS) disiasat 
menggunakan ekstrak etanol (ET), ekstrak 50% air-etanol (EW) dan ekstrak air (W) 
daripada tumbuhan ini. Ekstrak yang mempunyai aktiviti antiangiogenik paling 
tinggi, iaitu ET telah menunjukkan kesan antiobesiti secara in vivo. Walau 
bagaimanapun, aktiviti ke atas enzim lipase pankreas adalah sederhana dengan 
ekstrak ET menunjukkan aktiviti yang paling tinggi diikuti oleh ekstrak EW dan W. 
Kesan menghalang percambahan sel preadipocyte (3T3-L1) turut diperhatikan dan 
ekstrak ET menunjukkan aktiviti paling kuat diikuti oleh ekstrak EW dan W. Aktiviti 
antiangiogenik dan profil kimia OS juga dikaji yang melibatkan sampel daripada 
lima lokasi berbeza diseluruh Semenanjung Malaysia iaitu Batu Kurau (BK), Kepala 
Batas (KB), Sik Kedah (S), Changkat Jering (CJ) dan Sungai Buloh (SB). Sampel 
dari ladang BK menunjukkan aktiviti antiangiogenik paling kuat diikuti oleh SB, CJ, 
KB dan S. Profil kimia menggunakan Principal Component Analysis (PCA) dan 
High Performance Thin Layer Chromatography (HPTLC) mendedahkan bahawa 
ekstrak W mempunyai kandungan fitokimia terendah (fenolik dan flavonoid) diikuti 
ekstrak EW dan ekstrak ET. Kesan ujikaji ekstrak ET ke atas tikus menunjukkan 
penurunan berat badan yang ketara yang berkadar langsung dengan peningkatan dos. 
Kesan penurunan berat badan (P<0.01) dinilai secara peratusan pengurangan berat 
tisu adipos berbanding berat badan. Apabila ekstrak etanol OS diberikan pada tikus 
secara oral pada dos 250mg/kg (0.86±0.2%), didapati peratusan berat tisu adipos 
xvii 
 
lebih rendah berbanding dengan kumpulan HFD (2.19±0.2%). Berat tikus pada akhir 
rawatan menunjukkan bahawa ekstrak etanol mencegah peningkatan berat badan 
pada dos 500mg/kg dengan peningkatan berat sebanyak 7% berbanding kumpulan 
HFD yang menunjukkan peningkatan berat sebanyak 31% daripada berat badan 
awal. Ekstrak etanol juga menghalang steatosis hati yang disebabkan HFD sepanjang 
tempoh kajian. Merujuk kepada profil lipid, kami mendapati bahawa ekstrak etanol 
menyebabkan penurunan paras kolesterol (TC) dan trigliserida (TG) yang ketara dan 
berkadar langsung dengan penigkatan dos. Pada dos 500mg/kg, didapati paras TG 
dan TC masing-masing adalah 2.02±0.1mmol/L dan 0.29±0.08mmol/L berbanding 
kumpulan HFD (TG-3.03±0.1mmol/L; TC-0.64±0.14mmol/L). Profil HDL dan LDL 
bagi semua kumpulan yang dirawat dengan ekstrak OS menunjukkan bahawa ia 
berjaya menurunkan paras LDL dalam darah dan mengurangkan risiko penyakit 
jantung. Ini disokong dengan keputusan indeks plasma atherogenik (AIP) yang 
digunakan untuk meramal risiko penyakit kardiovaskular. Rawatan HFD+OS 
menunjukkan risiko mendapat penyakit kardiovaskular semakin berkurangan dengan 
peningkatan dos ekstrak (OS-125 AIP = -0.51, OS-250 AIP = -0.53 dan OS-500mg 
/kg AIP = -0.73) berbanding kumpulan HFD (-0.31). Selain itu, ekstrak etanol OS 
secara jelas menurunkan paras AST dan ALT dalam darah dan ini membuktikan 
bahawa ekstrak OS mempamerkan kesan perlindungan hati. Ini adalah selari dengan 
keputusan histologi hati yang mempamerkan kesan perlindungan terhadap hati 
berlemak kesan pengambilan HFD. Secara keseluruhan, keputusan menunjukkan 
bahawa ekstrak etanol OS menunjukkan aktiviti antiangiogenik yang kuat telah 
mempamerkan kesan antiobesiti yang berkemungkinan sesuai untuk mengurangkan 
berat badan serta risiko penyakit kardiovaskular. Hasil kajian juga menunjukkan 
xviii 
 
bahawa aktiviti ini adalah amat bergantung kepada kawasan geografi dan juga cara 
penanaman sesuatu spesis tumbuhan. 
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ETHANOL EXTRACT OF ORTHOSIPHON STAMINEUS BENTH. 
EXHIBITS ANTIOBESITY EFFECT BY INHIBITING ANGIOGENESIS 
AND PANCREATIC LIPASE 
 
ABSTRACT 
 
In this study, the antiobesity effect of Orthosiphon stamineus (OS) was 
investigated using ethanol extract (ET), 50% ethanol-water extract (EW) and water 
extract (W) of this plant species. Ethanol extract with the most potent antiangiogenic 
activity showed a significant antiobesity property in vivo. However, the activity 
towards the pancreatic lipase enzyme was modest with ET being the most potent 
followed by EW and W in decreasing order of reactivity. Activity towards inhibition 
of preadipocyte cell proliferation (3T3-L1) was also observed with ET being the 
most potent followed by EW and W. The antiangiogenic activity and chemical 
profile of OS collected from five different locations throughout peninsular Malaysia 
was also studied namely Batu Kurau (BK), Kepala Batas (KB), Sik Kedah (S), 
Changkat Jering (CJ) and Sungai Buloh (SB). BK plantation showed the most potent 
antiangiogenic activity with percentage of microvessels inhibition of 96.6±2.0%, 
followed by SB, CJ, KB and S. Chemical profiling using Principal Component 
Analysis (PCA) and High Performance Thin Layer Chromatography (HPTLC) reveal 
that W had the lowest amount of phytochemicals (phenolic and flavonoid) followed 
by EW and ET in increasing order. Treatment with the ET extract revealed 
significant weight loss effect in dose-dependent manner. Significant weight loss 
effect (P<0.01) was observed as the percentage of adipose tissue weight relative to 
body weight is reduced with oral feeding of the ET extract at dose 250 mg/kg 
(0.86±0.2%) compared to the HFD control group (2.19±0.2%). Weight of the rats 
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measured at the end of the treatment showed ethanolic extract prevent weight gain at 
dose of 500 mg/kg with only 7% increase of body weight compared to HFD group 
that showed 31% increase of body weight relative to initial weight. The ET also 
prevents HFD induced liver steatosis throughout the treatment period. From the lipid 
profile results, we found that ET significantly decreased cholesterol (TC) and 
triglyceride (TG) level in dose-dependent manner. At dose of 500 mg/kg the TG and 
TC were found to be 2.02±0.1mmol/L and 0.29±0.08mmol/L, respectively compared 
to HFD obese animals (TG- 3.03±0.1mmol/L; TC-0.64±0.14mmol/L). The HDL and 
LDL profile of the OS treated groups also showed significantly higher HDL level 
and lower in LDL level, suggesting that the extract may help to reduce the risk of 
heart disease. This is supported with the result of the atherogenic index of plasma 
(AIP) for prediction of risk of the cardiovascular event. Surprisingly, treatment of 
HFD+ET reduce the cardiovascular risk in a dose-dependent manner (OS-125 AIP = 
-0.51, OS-250 AIP = -0.53 and OS-500mg/kg AIP = -0.73, respectively) compared to 
HFD (-0.31) control.  From the AST and ALT result, ET showed markedly lower 
AST and ALT level compared with HFD control group, suggesting that the OS 
extract exhibits a liver protective effect. This is consistent with the liver histology 
that ethanolic extract of OS prevents fatty liver disease. Overall, the results suggest 
that ET with strong anti-angiogenic activity showed a significant antiobesity effect 
and potentially useful for weight reduction as well as lowering the risk of 
cardiovascular diseases. The finding also shows that this activity is strongly 
dependent on the geographical location, specifically Batu Kurau plantation where the 
planting condition e.g. amount of water and sunlight, fertilizer as well as soil type are 
properly controlled.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Obesity 
Obesity refers to abnormal or excessive fat accumulation in the body that 
presents a risk to health. Increase in adipocytes numbers and size contributes towards 
obesity. Proliferation and differentiation of adipocytes as well as fat accumulation 
are direct causes of obesity (Rohana and Roji 2011). Undoubtedly, obesity results 
from an imbalance between energy intake and expenditure that develops risk to 
metabolic disorders, atherosclerosis and diabetes (type 2) which have been affecting 
over 50% of adult population (Wellen and Hotamisligil 2003). Previous studies have 
shown that obesity facilitates development of chronic diseases such as inflammation-
based pathologies, stroke, osteoarthritis, cancers, hypertension, sleep apnoea, and 
arthritis (Hotamisligil 2003, Singla 2010, González-Castejón and Rodriguez-Casado 
2011). Age, developmental stage, physical activities and dietary habit are 
contributing factors that lead to excessive fat deposition in adipose tissues and other 
vital organs (Singla 2010).  
Body mass index (BMI), a measure of weight relative to height, is used as the 
key assessment tool in measuring the degree of overweight index. Correspondingly, 
according to the Global Health Observatory (GHO) data from WHO, the median 
BMI in equivalence to optimum health for an adult population is in the range of 21- 
23 kg/m
2
, BMI of more than 30 kg/m
2
 is considered severely obese, whereas BMI of 
more than 40 kg/m
2
 increase the risk rate of mortality. According to a report of 
World Health Organisation (WHO) in 2008, 35% of adults aged more than 20 years, 
were overweight, with BMI ≥ 25 kg/m2 (34% men and 35% of women) (WHO 
2014). The statistic shows evidence of increased prevalence of obesity around the 
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world and Malaysia in 2010 has been ranked by WHO sixth as the country with 
highest obesity rate in Asia (Verma, Chua et al. 2013). Therefore, there is a need to 
combat obesity and promote a healthy lifestyle.  
 
1.1.1 Causes of Obesity 
The etiology of obesity is complex and it does not have a simple and 
straightforward cause. Adipocytes have been shown to influence the pathogenesis of 
obesity-related disease due to its function as endocrine organ. Adipocytes apart from 
storing cell for fat and calories as triglycerides, also function as an active endocrine 
organ that communicates with the brain and peripheral tissue to secrete a variety of 
protein factors including chemokines, cytokines and hormone-like factors such as 
leptin, adiponectin and resistin (Calabro and Yeh 2007, German 2010). As body fat 
mass increases in obesity, enlargement of adipocytes causes molecular and cellular 
alteration affecting systemic metabolism where the concentration of anti-
inflammatory adipokines is reduced and pro-inflammatory adipokines is increased 
(Figure 1.1). In addition, release of free fatty acids (FFA) and glycerol from adipose 
tissues also increased affecting the function of insulin in tissue to become resistant. 
The FFA causes an increase in hepatic output of glucose and triglycerides in the form 
of very low density lipoprotein (VLDL) that cause insulin resistance in muscle or 
hyperglycaemia. Accumulation of FFA in muscle cells and excess insulin secreted 
from the pancreas in response to high hepatic glucose production causes 
hyperinsulinemia. Altogether, hyperglycaemia and hyperinsulinemia increase blood 
pressure contributing to hypertension (Jung and Choi 2014).  
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Figure 1.1 Endocrine function of adipose tissue and secretion of inflammatory 
adipokines in obese state (Jung and Choi 2014) 
 
 
The endocrine function of adipose tissue undoubtedly has a strong association 
with obesity associated metabolic syndrome. There are more than 50 adipokines that 
have been identified with their functional roles to control metabolic functions, but 
most studies have been focusing more on the activities of leptin and adiponectin. The 
discoveries of leptin and adiponectin produced mainly by the adipose tissue have 
been shown to communicate with brain and peripheral organs to regulate energy 
homeostasis, glucose and lipid metabolism and cardiovascular function. Release of 
angiotensinogen, a potent vasoconstrictor with relation to excess body fat has 
increase hypertension. Inflammation of adipose tissues has induce higher expression 
of pro-inflammatory proteins such as TNF-α, interleukin-6 (IL-6), monocytes 
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chemotactic protein 1 (MCP-1), inducible nitric oxide synthase (iNOS), transforming 
growth factor β1 (TGF- β), procoagulant proteins such as plasminogen activator 
inhibitor type 1 (PAI-1), tissue factor and factor VII (Greenberg and Obin 2006, Jung 
and Choi 2014). 
High amounts of adipose tissues are also associated with the increased 
number of macrophages where they function to scavenge moribund adipocytes. 
Adipocyte precursors also have potent phagocytic capacity and in response to 
specific stimuli, they can be transformed into macrophages-like cells that are present 
in obese compared to lean individual (Charrière, Cousin et al. 2003). This strongly 
supported by (Weisberg 2003) with evidence that macrophage infiltration of adipose 
tissue is characteristic of human obesity. This correlated with the report by (Jung and 
Choi 2014) that obesity induces switch of adipose tissue phenotypic from anti-
inflammatory (M2) to pro-inflammatory (M1) macrophages. 
In summary, the causes of obesity is mainly due to excessive number and 
enlargement of adipocytes that leads to dysregulated secretion of adipokines and 
increased release of free fatty acids (FFA) that modify the inflammatory responses, 
therefore contributing to development of metabolic disorder. 
 
1.1.2 Current Treatment for Obesity 
Modern lifestyle and unhealthy eating habits result in increased number of 
health related problems including obesity. According to (WHO 2015), out of 1.9 
billion of adults population in 2014, 18 years and older were overweight. Out of this 
population, over 600 million were obese. Current available treatments for obesity 
include appetite suppressants or anorexics that control food intake by modulating the 
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central nervous system. Sibutramine (serotonin and noradrenalin re-uptake inhibitor) 
and rimonabant (cannabinoid receptor antagonist) are preeminent examples. These 
treatments require new options such as sibutramine which can cause constipation and 
headache with minimum weight loss (Luque and Rey 1999). The use of rimonabant 
was terminated due to serious psychiatric side-effects (Leite, Mocelin et al. 2009). 
Other treatment involves drugs that inhibit the absorption of specific nutrients in 
food such as orlistat by inhibiting pancreatic lipase and therefore reduce systemic 
absorption of dietary fat (Korner and Aronne 2004, Seo, Choe et al. 2011). However, 
orlistat was reported to cause steatorrhea and increase risk of developing deficiencies 
in lipid soluble vitamins and essential fatty acids (Heck, Yanovski et al. 2000). 
Gastric bypass surgery or bariatric surgery are alternative options 
recommended for severely obese individuals who suffer from serious health problem 
related to obesity that is hard to be treated with diet and physical exercise alone. 
Bariatric surgery is an approach to help lose weight by surgery on the stomach and/or 
intestines that subsequently restrict food intake and promote weight loss as well as 
reducing risk of type 2 diabetes. However, the best results can be achieved when the 
patients follow healthy eating habit and regular exercise. Undeniably, the cost for the 
surgery is quite high and some side effects have been identified, include bleeding, 
infection, leaks at the site where intestines were sewn together, diarrhoea and blood 
clots that may affect lungs and heart. Moreover, deficiency in nutrient absorption 
also has been reported (NIH 2011). Hence, a better option of obesity treatment 
should be explored to overcome the side effect of taking synthetic drugs and surgery.  
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1.1.3 Angiogenesis and Obesity 
Angiogenesis is a process of new capillary blood vessels from existing blood 
vessel and it is an important natural process that occurs for healing and reproduction 
process (Adair and Montani 2010). The process is controlled by the body through a 
balanced production of growth and inhibitory factors in healthy tissues. Disturbances 
in the body production of specific growth and inhibitory factors may lead to an 
excessive and insufficient growth of blood vessel that directly affects the health of an 
individual. The excessive blood vessel proliferation may cause tumor growth and 
spread, it may also cause rheumatoid arthritis, diabetic blindness, psoriasis, obesity 
and others. In this scenario, the new blood vessel nourishes the diseased tissues and 
some of the new blood vessels are in fact abnormal and leaky which may damage 
normal tissues. On the contrary, insufficient blood vessel formation may cause 
infertility, heart disease, stroke, ulcers and scleroderma. The insufficient blood 
vessels formation causes improper restoration of blood circulation and increases the 
risk of tissue death (Koch 2003, Adair and Montani 2010, Kumar, Kavimani et al. 
2012). 
The angiogenesis in relation to obesity is not fully established. However, the 
increase in proliferation and differentiation of adipocytes has been previously 
reported by many other researchers who have shown strong association between 
these two pathology (Bråkenhielm, Cao et al. 2004, Voros, Maquoi et al. 2005, Cao 
2007, Nishimura, Manabe et al. 2007, Lijnen 2008, Christiaens and Lijnen 2010). 
The adipose tissue undergoes expansion and regression throughout adult life and this 
requires parallel growth of the capillary network to support the survival of the 
tissues. Thus, adipose tissues are among the tissues that have highest angiogenic 
capacities (Lemoine, Ledoux et al. 2013).  
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 Ledoux, Queguiner et al. (2008) have outlined the role of angiogenesis in 
development of fat cells and their study has found that the adipose tissue from 
severely obese adults grafted on chick chorioallantoic membrane (CAM) was able to 
recruit its own endothelial cells to induce angiogenesis (Ledoux, Queguiner et al. 
2008). Apart from that, adipose tissue previously reported to promote wound healing 
and revascularize ischemic tissues of myocardium, suggested that adipose tissue 
produces angiogenic molecules. Their finding has shown the link of adipogenesis 
and angiogenesis apart from other factors that promote adipose tissue angiogenesis 
such as hyperplasia, hypoxia and inflammation (Hausman and Richardson 2004, Cao 
2007, Nishimura, Manabe et al. 2007). 
Adipocytes apart from fat storing organ, form as an important endocrine 
organ that secretes a variety of protein factors including chemokines, cytokines and 
hormone-like factors such as leptin, adiponectin and resistin (German 2010). 
Hausman and Richardson (2004) in their review indicate that adipogenesis is 
regulated by factors that drive angiogenesis. Vascular endothelial growth factor 
(VEGF) is the most critical growth factor in initiating the formation of immature 
blood vessels. In addition, the expression of VEGF is influenced by hypoxia, insulin, 
growth factors and several cytokines which are directly connected with the endocrine 
function of adipocytes (Hausman and Richardson 2004). This is supported by 
Nishimura et al. (2007) in their live-cell imaging study of unfixed living adipose 
tissue labelled with a combination of lectin (red), BODIPY (blue), acetylated LDL 
(blue) and Hoechst 33342 (green) in db/db mice (Nishimura, Manabe et al. 2007). 
The study revealed that adipogenesis of the adipose tissue takes place within 
adipogenic/angiogenic cell clusters that contain various stromal cell and blood 
vessels. This also further determined with administration of anti-VEGF antibodies to 
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the mice and it inhibited not only angiogenesis but also the formation of 
adipogenic/angiogenic cell clusters. This clearly indicates that coupling of 
adipogenesis and angiogenesis is essential for the differentiation of adipocytes in 
obesity and VEGF is the mediator of the process. 
A review by Daquinag et al. (2011) on vascularization of adipose tissue as an 
anti-obesity approach also indicates the roles of angiogenesis in an expansion of 
white adipose tissue (WAT). Development of obesity as a result of adipocytes 
hypertrophy (increase in cell size) as well as hyperplasia (increase in cell number) 
associated with the expansion of WAT that requires angiogenesis to feed the process. 
Depletion of nutrient and oxygen through inhibition of WAT neovascularization can 
prevent an onset of obesity in both genetic and diet-induced obesity models and this 
has been previously reported with the use of an anti-angiogenic drug to inhibit WAT 
expansion (Daquinag, Zhang et al. 2011). Rupnick et al. (2002)  in their study has 
shown that the genetically obese leptin-deficient mice from different obesity model 
treated with anti-angiogenic agent (TNP-470, angiostatin (kringle 1-4 domains of 
plasminogen), endostatin (a C-terminal fragment of collagen XVIII), Bay-129566 (a 
matrix metalloproteinase inhibitor) and thalidomide resulted weight reduction and 
adipose tissue loss in dose-dependent manner. The treated mice showed decreased in 
endothelial proliferation and increase in apoptosis when compared with the control 
group, evidence that adipose tissue mass can be regulated by its vasculature 
(Rupnick, Panigrahy et al. 2002). This is strongly supported by Bråkenhielm et al. 
(2004) in their study using systemic administration of angiogenesis inhibitor, TN-470 
(AGM-1470) tested on high caloric diet-fed wt mice as well as in genetically leptin-
deficient ob/ob mice. They have shown reduction in adipose tissue vascularization 
that selectively affects the growth of adipose tissue with a decreased in insulin and 
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serum level of low density lipoprotein cholesterol (LDL-C) indicating that expansion 
of adipose tissue can be controlled via angiogenesis inhibitor (Bråkenhielm, Cao et 
al. 2004).  
Another study by (Voros, Maquoi et al. 2005) on angiogenesis modulation 
during development of adipose tissue tested in murine models of obesity showed that 
fat pad growth in both nutritionally induced or genetic obesity in mice is 
accompanied by increased vascularization. They suggested the potential role of pro- 
and antiangiogenic factors in obesity-related angiogenesis similar as reported by 
Hausman and Richardson (2004) on VEGF signalling modulation that affects the 
development of adipose tissue in obesity (Hausman and Richardson 2004). Cutchins 
et al. (2012) in their study correlate VEGF expression in angiogenesis with the 
function of the inhibitor of differentiation-3 (Id3) released during expansion of 
adipocytes. The expanding adipose tissue results in hypoxia that induces VEGF 
expression by adipocytes. However, in the Id3-deficient mice model shows that the 
expression of VEGFA was attenuated, causing a decrease in microvascular blood 
volume in the adipose tissue (Cutchins, Harmon et al. 2012). This further supports 
the concept that inhibition of angiogenesis in adipose tissue may prevent obesity. 
The natural compounds with antiangiogenic properties also have been 
reported to have a positive effect on the treatment of obesity. (Kim 2010) in his 
patent report discovered that Psoraleae semen extract, Sieges beckie herbal extract 
and Corni fructus extract which exhibit antiangiogenesis effect also demonstrated 
antiobesity activity. Furthermore, Mojzis et al. (2008) in their review summarize the 
potential of bioactive plant compounds specifically flavonoid and chalcones in 
angiogenesis modulation by regulating the expression of VEGF, matrix 
metalloproteinases (MMPs), EGFR and inhibit NFKB, PI3-K/Akt, ERK1/2 signalling 
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pathways, causing strong antiangiogenic effects (Mojzis, Varinska et al. 2008). In 
addition, various studies on plant rich flavonoid has shown significant antiobesity 
effect such as green tea extract (Chantre and Lairon 2002, Lin, Della-Fera et al. 
2005), Lotus leaf extract (Du, You et al. 2010), Morus bombycis root extract (Kim, 
Lee et al. 2010), Nelumbo nucifera leaves extract (Ono, Hattori et al. 2006) etc. 
which support that natural antiangiogenic agent also is a promising therapeutic agent 
for the treatment of obesity. 
Overall, recent evidence on angiogenesis modulation as the target to prevent 
the growth of adipose tissue may offer a better option in the treatment of obesity and 
other related metabolic disorder. Anti-angiogenic therapy from natural sources with 
promising therapeutic efficacy should be further explored to combat obesity with 
lower risk of side effects. 
 
1.2 Potential of Herbal Extract as Antiobesity Agent 
Herbal medicines have received great attention as alternative medicines due 
to increase awareness on the high therapeutic values of natural products. The demand 
promotes more scientific study to ensure safety, quality and efficacy of the herbal 
medicine. Herbal medicine also called botanical medicine or phytomedicine is 
basically the application of the plant material such as root, leaves, bark, flowers, 
seeds and berries used in the maintenance of health, prevention, diagnosis and 
improvement or treatment of the illness. Herbal medicine has been in existence since 
ancient times and is the oldest treatment system in the world. The naturally occurring 
chemicals and compounds found in plant that is effective in healing various illnesses 
is a key for herbal medicine practice worldwide. The value of herbal medicine in 
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preventing and treatment of illness has increased due to improvement in analysis and 
quality control as well as advances in scientific research.  
Extensive studies have been carried out by researchers to identify the value of 
plants and its constituents in lowering the risk of obesity and related metabolic 
syndrome. Several plant extracts such as Sorbus commixta (Japanese rowan), Viscum 
album (European mistletoe), Rosmarinus officinalis (rosmary), Morus bombycis 
(mulberry), and Ginkgo biloba (ginkgo) have been reported for their potent lipase 
inhibitory effect that may help in reducing dietary fat absorption with IC50 value less 
than 20 µg/mL (Kim, Lee et al. 2010, Yasser Bustanji 2010, Bustanji, Al-Masri et al. 
2011, Lee, Kim et al. 2012). In other studies, green tea extract standardized to 
contain 25% catechin had direct inhibition on gastric and pancreatic lipases as well 
as stimulation of thermogenesis in its action of reducing fat accumulation in a body 
(Chantre and Lairon 2002). Potent secondary metabolites mainly phenolic and 
flavonoid from plant extract have been reported to contribute to this activity. 
Catechin, epicatechin and epigallocatechin gallate (EGCG) from Camellia sinensis 
(tea), Morinda citrifolia (noni), Centella asiatica (pegaga) and Momordica charantia 
(bitter gourd) were found to inhibit proliferation and differentiation of preadipocytes 
as well as potent pancreatic lipase, suggested the potential of these plant extracts as 
antiobesity agents (Lin, Della-Fera et al. 2005, Sahib, Hamid et al. 2011, Sergent, 
Vanderstraeten et al. 2012).  
The approach on using plant and herbal extracts has great potential in 
combating diseases including obesity. Current interest in finding scientific evidence 
on safety and efficacy of herbal medicine becoming an alternative for development 
of new antiobesity agents as they were previously reported to contain high 
antioxidant properties which are the key to lowering risk of many diseases (Zhang, 
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Gan et al. 2015). This study aims to evaluate anti-obesity activity of Orthosiphon 
stamineus (Misai Kucing) extracts in vitro and in vivo.  
 
1.3 Orthosiphon stamineus Benth. 
Orthosiphon stamineus Benth., commonly known as Misai Kucing or Cat’s 
whiskers is herbaceous shrub from the family of Lamiaceae. It has wispy stamens of 
its flower shaped look like cat’s whiskers (Figure 1.2). Leaves of this plant are used 
commonly in Southeast Asia and European countries for herbal tea, widely known as 
Java tea. The old folk’s practice of this plant reported on the use to treat menstrual 
disorder, gallstone, influenza, hepatitis and jaundice (Ahamed Basheer and Abdul 
Majid 2010). Moreover, this plant has been used traditionally as a diuretic agent and 
to treat kidney and bladder inflammation, gout, diabetes, rheumatism, abdominal 
pain, allergy, inflammation and hypertension (Ahamed Basheer and Abdul Majid 
2010, Ismail, Hanapi et al. 2010).  
 
1.3.1 Classification and Description 
 
Table 1.1 Taxonomy classifications of O. stamineus 
 
Family :  Lamiaceae 
Genus :  Orthosiphon 
Species :  stamineus 
Scientific name :  Orthosiphon stamineus (Benth) 
Vernacular name : Misai Kucing (Malaysia); Cat’s whiskers 
(English); Kumis Kucing (Indonesia); 
Mao Xuhua (China) 
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Figure 1.2 Photographs of Orthosiphon stamineus flower and leaves 
 
1.3.2 Chemical Constituents and Pharmacological Properties of O. stamineus 
Various studies on O. stamineus revealed a range of chemical compounds. 
According to an Assessment Report by a European Medicinal Agency (EMA) 
released in 2010, the compound identified from this plant include mineral (potassium 
3%), diterpenes (orthosiphols A-E 0.2%), triterpenes, essential oil (0.02-0.06%), 
sesquiterpenes, lipophilic flavones like sinensitin (0.1-0.19%), isosenensitin and 
euphatorin flavonol glycosides; rosmarinic acid (0.1-0.5%), and other caffeic acid 
derivatives like mono and dicafeyl tartaric acid as well as lithospermic acid, 
phytosterols (β-sitosterol) and essential oil (0.7%), isositol, pimarane, isopimarene 
and staminane diterpenes, triterpenes (ursolic acid, oleanolic acid, betulinic acid, 
hydroxybetulinic acid, maslinic acid, α-amyrin, β-amyrin), and chromenes (Hossain, 
Salehuddin et al. 2006, HMPC 2010, Hossain and Ismail 2013).  
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Figure 1.3 The structure of the chemical constituents (A- Rosmarinic acid, B- 3
′
-
hydroxy-5,6,7,4
′
-tetramethoxyflavone, C- Sinensitin, D- Eupatorin, E- Oleanolic 
acid, F- Ursolic acid and G- Betulinic acid) commonly found in O. stamineus 
extracts. 
 
In addition to the components mentioned, Awale et al. (2003) have reported 
that O. stamineus also consists of oxygenated sesquiterpenes (Awale, Tezuka et al. 
2003). Figure 1.3 showed the chemical structure of the compounds commonly found 
in O. stamineus extracts. 
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Scientific studies have shown that extracts of O. stamineus leaves exhibit 
range of pharmacological properties such as antibacterial, antioxidant, 
hepatoprotective effect against paracetamol-induced liver damage and thioacetamide-
induced hepatotoxic model  rats, chemopreventive activity against human 
hepatocellular carcinoma cell line, HepG2, nephroprotective activity in rats  and 
others. Moreover, O. stamineus extract is widely reported to have strong antioxidant 
properties. A study conducted by Chin et al. (2008) recorded that O. stamineus has 
strong antioxidant activity in vivo as the extract of the herb enhance the activity of 
hepatic glutathione-s-transferase in rat livers and the effect seen was dose-dependent 
(Chin, Ismail et al. 2008 ). Various researchers  have worked extensively on various 
parts of the plant with different solvent as well as supercritical CO2 extracts and 
proved that O. stamineus has various polyphenols, flavonoid and other bioactive 
phytoconstituents which attribute to its antioxidant property (Akowuah, Zhari et al. 
2004, Akowuah, Ismail et al. 2005, Yam, Basir et al. 2007, Ahamed Basheer and 
Abdul Majid 2010, Ho, Noryati et al. 2010, Abdelwahab, Mohan et al. 2011, Farhan, 
Razak et al. 2012, Yam, Lim et al. 2013). A report by (Sahib 2009) revealed that the 
presence of a high level of anti-oxidants and phenolic content compounds in O. 
stamineus extract exhibit a strong antiangiogenic properties. Moreover, flavones 
eupatorin standard in comparison with chloroform extract of O. stamineus which rich 
in flavones eupatorin was found to inhibit migration of human umbilical vein 
endothelial cells (HUVECs) and contribute to significant antiproliferative effect 
against various cancer cells (Doleckova, Rarova et al. 2012). Ahamed et al. (2012) 
also reported the ability of O. stamineus extract to inhibit migration as well as tube 
formation of HUVECs by suppressing VEGF-induced phosporylation of VEGF 
receptor-2 in HUVECs with the phytochemicals profile showed higher amount of 
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rosmarinic acid, protein and phenolic contents (Ahamed, Aisha et al. 2012). Strong 
antiangiogenic property of O. stamineus indicates that this plant has higher potential 
for the treatment of various diseases involving modulation of vasculature including 
obesity. 
Apart from that, the extracts of O. stamineus was found to be safe with no 
sign of toxicity effect in vitro and in vivo which suggested that it could be the safe 
natural source for treatment of critical diseases (Maheswari, Maryammal et al. 2008, 
Ahamed Basheer and Abdul Majid 2010, Kannappan, Madhukar et al. 2010, 
Alshawsh, Abdulla et al. 2011, Salleh, Rajab et al. 2011).  
 
 
1.4 Hypothesis 
1. O. stamineus has anti-obesity properties due to its anti-angiogenic 
properties. 
2. Extract that contain the highest amount of phenolic and flavonoid 
compounds gives the strongest anti-obesity property. 
3. Influence of localities on phenolic and flavonoid constituents affects 
antiangiogenic and anti-obesity properties. 
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1.5 General objective 
To study the antiobesity property of Orthosiphon stamineus extracts and to establish 
the chemical profile in relation to its antiobesity effect. 
 
 
1.6 Research objectives 
1. To evaluate anti-obesity effect of O. stamineus extract in vivo and in vitro 
via its anti-angiogenic property. 
2. To determine the amount of phenolic and flavonoid content of various 
solvent extract of O. stamineus from various locations. 
3. To develop the quality control parameter by establishing the chemical 
profiles and general quality assessment of O. stamineus leaves extracts as 
an antiobesity agent. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Materials and Chemicals 
 
10% Formalin Sigma-Aldrich, Germany 
3T3-L1 Cells ATCC, Rockville, MD, USA  
6-aminocaproic acid Sigma-Aldrich, Germany 
Aluminium chloride  Sigma-Aldrich, Germany 
Amphotericin B (Fungizone) Sigma-Aldrich, Germany 
Aprotinin Sigma-Aldrich, Germany 
Dimethyl sulfoxide  Sigma-Aldrich, Germany 
Dulbecco’s Modified Eagle’s Medium (DMEM) Gibco, Life Technology, UK  
Earle’s Salt (M199) medium  Gibco, Life Technology, UK 
Ethanol  Riedel-de Haën, Germany  
Ethyl acetate Riedel-de Haën, Germany 
Foetal bovine serum (FBS) Gibco, Life Technology, UK 
Fibrinogen Calbiochem, USA  
Folin-Ciocalteu reagent Sigma-Aldrich, Germany 
Formic acid  Fisher Scientific, USA  
Gallic acid  Sigma-Aldrich, Germany 
Gentamicin injection B.P 80 mg / 2 mL  Sigma-Aldrich, Germany 
Hexane QRëc™, Germany 
Hydrochloric acid QRëc™, Germany  
L-glutamine Sigma-Aldrich, Germany 
Lipase (Type II; crude from porcine pancreas) Sigma-Aldrich, Germany 
Methanol  Riedel-de Haën, Germany 
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Orlistat TOCRIS Bioscience, UK 
Penicillin-streptomycin solution Gibco, Life Technology, UK 
Phosphate buffered saline (PBS)  Sigma-Aldrich, Germany 
p-Nitrophenyl butyrate  Sigma Chemical Co. (LLC) 
Potassium acetate  Sigma-Aldrich, Germany 
Quercetin Sigma-Aldrich, Germany 
Sodium carbonate  Sigma-Aldrich, Germany 
Sulphuric Acid  Sigma-Aldrich, Germany 
Suramin  Sigma-Aldrich, Germany 
Thrombin 1000 unit Sigma-Aldrich, Germany 
Tris-HCl buffer Sigma Chemical Co. (LLC) 
Trypsin Gibco, Life Technology, UK  
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
2.2 Apparatus and Equipments 
 
6-,12-, 24-, 48- and 96-well plates  Corning, USA  
Autoclave Hirayama, Japan  
Biosafety cabinet ESCO, USA 
Cell culture flasks (25 and 75 cm
2
)  BD Bioscience, USA 
Disposable petri dishes Sterilin, UK 
Dissecting set AVEAids, Malaysia 
Erlenmeyer flasks Schott Duran, Germany 
Filter papers Whatman, USA 
Fluorescence microscope (EVOS)  AMG, USA  
Freeze dryer  Labconco, USA 
Fourier Transform Infrared Spectrometer (FTIR) Perkin Elmer, USA 
Fume hood ESCO, USA 
Grinder Retsch GmbH, Germany 
Haemocytometer  Marienfeld, Germany  
High Performance Thin Layer Chromatography 
(HPTLC) 
Camag, Switzerland 
Muffle Furnace Thermolyne, USA 
Carbon dioxide incubator Fisher Scientific, Germany  
Incubator shaker Sartorius, Germany  
Inverted light microscope  Olympus, Japan  
Microcentrifuge tubes Eppendorf, Germany 
Micropipettes Eppendorf, Germany 
Microplate reader Tecan, Switzerland 
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Multiwave3000 Microwave  Perkin Elmer, USA 
Minisart filter 0.22 μm  Sartorius, USA 
Needles Becton Dickinson, USA 
Oven Memmert, Germany 
pH meter  Oakton, USA 
Refrigerator  Samsung, Korea 
Rotary evaporator Buchi, Switzerland 
Round bottom flasks Favorit®, Thailand 
Screw cap centrifuge tubes  Axygen®, USA  
Serological pipettes  BD Falcon, USA  
Syringes  Becton Dickinson, USA  
Thin layer chromatography plates  Merck, USA  
Ultrasonic cleaner UC-10 Lab Companion™, China 
Universal fit pipette tips  Corning Inc., USA  
UV Spectrophotometer Lambda 45,  Perkin Elmer, USA  
Volumetric flasks  Pyrex, USA  
Vortex  VELP, Europe  
Water bath  Protech-Electronic, Malaysia  
Weighing Balance  Fisher Scientific, Germany 
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2.3 Sources of Plant Material and Authentication 
Fresh leaves of Orthosiphon stamineus were collected from 5 different 
locations throughout peninsular Malaysia, mainly from Batu Kurau, Kepala Batas, 
Sik, Changkat Jering and Sungai Buloh. The plant sample was authenticated and 
deposited at the Herbarium of School of Biology, Universiti Sains Malaysia with 
voucher number of 11009. Localities of Orthosiphon stamineus used in this study are 
summarised in the Table 2.1. 
 
Table 2.1 Location of Orthosiphon stamineus collected sample 
No. District State Code 
1 Batu Kurau Perak BK 
2 Kepala Batas Pulau Pinang KB 
3 Sik Kedah S 
4 Changkat Jering Perak CJ 
5 Sungai Buloh Selangor SB 
 
2.4 Gravimetric Analysis 
All gravimetric tests were carried out following the standard method stated in 
Malaysia Herbal Monograph Volume 1. 
 
2.4.1 Determination of Foreign Matter 
Leaf samples of Orthosiphon stamineus of approximately 100g were spread 
in a thin layer form on a piece of white paper. Foreign matter was sorted with the 
naked eye and with the use of a magnifying glass. The foreign matter found was 
separated; the weight and percentage was then calculated per 100 g of sample 
(Committee, Ismail et al. 1999). 
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2.4.2 Determination of Total Ash Content 
O. stamineus leaves samples of 5 g were weighed in tarred crucibles. Samples 
were then incinerated by increasing the temperature gradually, not exceeding 450°C 
until it is free from carbon. Then, the crucibles were cooled in a desiccator and the 
ash was weighed. Percentage of total ash content was calculated per gram of leaves 
sample (Committee, Ismail et al. 1999).  
 
2.4.3 Determination of Loss on Drying 
Plant materials of 2 g were weighed accurately in tarred flat-bottomed dishes. 
The samples were then dried in the oven at 100-105°C for 5 h until constant weight 
was achieved. Percentage of loss on drying with reference to the air dried sample was 
then calculated (Committee, Ismail et al. 1999). 
 
2.4.4 Determination of Extractive Value 
Five grams of powdered plant material was macerated separately for 24 h in 
100mL of 95% ethanol and 50% ethanol with constant agitation for 7 h. The solution 
was filtered with Whatman No. 1 filter paper and 20 mL of the filtrate was dried at 
105°C on watch glasses until constant mass. Then, a percentage of ethanol extractive 
value was measured against initial weight of the air dried powdered sample. 
In addition, percentage yield for water soluble extract was carried under 
reflux. Five grams of plant materials was dissolved in 100 mL of distilled water and 
refluxed for 1 h. The remaining extract solution was filtered and the 20 mL of the 
filtrate was transferred into watch glasses which have been preheated to constant 
weight. The filtrate was then oven dried at 105°C for 3 h. The water soluble 
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extractive value was calculated against the weight of the air dried powdered sample 
according to Ismail et al.(Committee, Ismail et al. 1999). 
 
2.5 Determination of Heavy Metal 
The  lead (Pb), cadmium (Cd), arsenic (As) and mercury (Hg) content present 
in Orthosiphon stamineus leaves were determined using Atomic Absorption 
Spectrometer (AAS) as per standard method of British Pharmacopoeia 2008 
(Commission 2008). Briefly, 0.5 g of dried powder of O. stamineus leaves was 
weighed and transferred into Teflon vessels. Ten millilitre of nitric acid was then 
added to the O. stamineus sample and  heated to 200°C under 120 psi pressure using 
microwave (Perkin Elmer, USA). The samples in triplicate were then diluted with 
50mL of distilled water and filtered with 2μm membrane syringe filter. The filtrates 
were then analysed using AAS against nitric acid as blank and standard reference of 
lead, cadmium, arsenic and mercury solution were prepared in 2% nitric acid. The 
plant samples were sent to KbioCorp Laboratory for analysis.  
 
2.6 Microbial Limit Test 
Powder dried leaves of O. stamineus were subjected to Microbial Limit Test 
(MLT) as per the British Pharmacopoeia 2008 method consisting of total viable 
aerobic count, total yeast and mould count, Escherichia coli, Staphylococcus aureus, 
Salmonella spp. and Pseudomonas aeruginosa count (Commission 2008). For total 
aerobic, yeast and mould count, 90 mL phosphate buffer at pH 7.2 was added to 10 g 
of dried powdered O. stamineus leaf. Then, 1 mL of the mixture was transferred into 
a petri dish prior containing 20 mL sterilized molten Soybean-Casein digest agar and 
